← Back to All US Stocks

HLYK Stock Analysis 2026 - HealthLynked Corp AI Rating

HLYK OTC Services-Offices & Clinics of Doctors of Medicine NV CIK: 0001680139
Recently Updated • Analysis: Apr 11, 2026 • SEC Data: 2025-12-31
STRONG SELL
92% Conf
Pending
Analysis scheduled

📊 HLYK Key Takeaways

Revenue: $2.1M
Net Margin: -158.8%
Free Cash Flow: $-1.7M
Current Ratio: 0.22x
Debt/Equity: N/A
EPS: $-1.16
AI Rating: STRONG SELL with 92% confidence

Is HLYK a Good Investment? Thesis Analysis

Claude

HealthLynked faces imminent financial distress with negative stockholders' equity of -$5.8M, only $37.1K cash reserves, and operating cash burn of -$1.7M annually. Revenue collapsed 31.3% YoY while the company burns cash at a rate that depletes remaining liquidity in approximately 3 weeks, creating acute solvency risk.

Why Buy HLYK? Key Strengths

Claude
  • + Exceptional gross margin of 90.7% demonstrates viable core unit economics in medical services delivery
  • + Net loss improved 46.5% YoY suggesting operational cost controls are taking effect
  • + Healthcare services sector has structural demand tailwinds if company survives liquidity crisis

HLYK Investment Risks to Consider

Claude
  • ! Negative equity of -$5.8M means liabilities exceed all assets - company is technically insolvent
  • ! Critical liquidity crisis: $37.1K cash against $7.5M liabilities with monthly burn rate exceeding available cash
  • ! Severe revenue decline of 31.3% YoY with no evidence of stabilization or recovery trajectory
  • ! Negative operating cash flow of -$1.7M and free cash flow margin of -83.1% indicate unsustainable operations
  • ! Current ratio of 0.22x shows inability to service short-term obligations from current assets

Key Metrics to Watch

Claude
  • * Monthly cash burn rate and estimated runway to insolvency/capital injection deadline
  • * Revenue trend reversal: Whether next quarter stabilizes the -31% YoY decline
  • * Operating cash flow return to positive: Critical survival metric given current burn
  • * Capital raise or debt restructuring announcements to address negative equity
  • * Customer acquisition cost versus lifetime value trends in medical services segment

HLYK Financial Metrics

Revenue
$2.1M
Net Income
$-3.3M
EPS (Diluted)
$-1.16
Free Cash Flow
$-1.7M
Total Assets
$1.7M
Cash Position
$37.1K

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

HLYK Profitability Ratios

Gross Margin 90.7%
Operating Margin -102.3%
Net Margin -158.8%
ROE N/A
ROA -192.7%
FCF Margin -83.1%

HLYK vs Default Sector

How HealthLynked Corp compares to Default sector averages

Net Margin
HLYK -158.8%
vs
Sector Avg 12.0%
HLYK Sector
ROE
HLYK 0.0%
vs
Sector Avg 15.0%
HLYK Sector
Current Ratio
HLYK 0.2x
vs
Sector Avg 1.8x
HLYK Sector
Debt/Equity
HLYK 0.0x
vs
Sector Avg 0.7x
HLYK Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is HLYK Overvalued or Undervalued?

Based on fundamental analysis, HealthLynked Corp has mixed fundamental signals relative to the Default sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
-158.8%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

HLYK Balance Sheet & Liquidity

Current Ratio
0.22x
Quick Ratio
0.22x
Debt/Equity
N/A
Debt/Assets
438.5%
Interest Coverage
-349.53x
Long-term Debt
$450.0K

HLYK 5-Year Financial Trend & Growth Analysis

HLYK 5-year financial data: Year 2019: Revenue $4.0M, Net Income N/A, EPS N/A. Year 2020: Revenue $4.7M, Net Income N/A, EPS N/A. Year 2021: Revenue $5.8M, Net Income -$5.8M, EPS $-0.04. Year 2022: Revenue $5.8M, Net Income -$10.4M, EPS $-0.05. Year 2025: Revenue $3.0M, Net Income -$6.1M, EPS $-2.18.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: HealthLynked Corp's revenue has declined by 25% over the 5-year period, indicating business contraction. The most recent EPS of $-2.18 indicates the company is currently unprofitable.

HLYK Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-83.1%
Free cash flow / Revenue

HLYK Quarterly Performance

Quarterly financial performance data for HealthLynked Corp including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $388.5K -$701.0K $-0.30
Q2 2025 $592.4K -$701.0K $0.00
Q1 2025 $774.2K -$1.1M $0.00
Q2 2023 $35.5K $448.5K $0.00
Q1 2023 $16.3K -$1.2M N/A
Q3 2022 $1.3M -$368.0K $0.00
Q2 2022 $1.4M -$505.8K $0.00
Q1 2022 $1.4M -$1.2M $-0.01

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

HLYK Capital Allocation

Operating Cash Flow
-$1.7M
Cash generated from operations
Stock Buybacks
$7.7K
Shares repurchased (TTM)
Capital Expenditures
$2.6K
Investment in assets
Dividends Paid
$2.3M
Returned to shareholders

HLYK SEC 10-K & 10-Q Filing Analysis

Access official SEC EDGAR filings for HealthLynked Corp (CIK: 0001680139)

📋 Recent SEC Filings

Date Form Document Action
Mar 31, 2026 10-K ea0282013-10k_health.htm View →
Feb 10, 2026 S-1 ea0275639-s1_health.htm View →
Feb 6, 2026 8-K ea0275101-8k_health.htm View →
Dec 12, 2025 8-K ea0269326-8k_health.htm View →
Nov 19, 2025 10-Q ea0265928-10q_health.htm View →

Frequently Asked Questions about HLYK

What is the AI rating for HLYK?

HealthLynked Corp (HLYK) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.

What are HLYK's key strengths?

Claude: Exceptional gross margin of 90.7% demonstrates viable core unit economics in medical services delivery. Net loss improved 46.5% YoY suggesting operational cost controls are taking effect.

What are the risks of investing in HLYK?

Claude: Negative equity of -$5.8M means liabilities exceed all assets - company is technically insolvent. Critical liquidity crisis: $37.1K cash against $7.5M liabilities with monthly burn rate exceeding available cash.

What is HLYK's revenue and growth?

HealthLynked Corp reported revenue of $2.1M.

Does HLYK pay dividends?

HealthLynked Corp pays dividends, with $2.3M distributed to shareholders in the trailing twelve months.

Where can I find HLYK SEC filings?

Official SEC filings for HealthLynked Corp (CIK: 0001680139) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is HLYK's EPS?

HealthLynked Corp has a diluted EPS of $-1.16.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is HLYK a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, HealthLynked Corp has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is HLYK stock overvalued or undervalued?

Valuation metrics for HLYK: ROE of N/A (sector avg: 15%), net margin of -158.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy HLYK stock in 2026?

Our dual AI analysis gives HealthLynked Corp a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is HLYK's free cash flow?

HealthLynked Corp's operating cash flow is $-1.7M, with capital expenditures of $2.6K. FCF margin is -83.1%.

How does HLYK compare to other Default stocks?

Vs Default sector averages: Net margin -158.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.22 (avg: 1.8).

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 11, 2026 | Data as of: 2025-12-31 | Powered by Claude AI